Hikma Pharmaceuticals (LON:HIK) had its target price decreased by from GBX 1,060 ($14.20) to GBX 865 ($11.58) in a research report sent to investors on Friday, November 10th. currently has a reduce rating on the stock.
A number of other brokerages have also weighed in on HIK. Citigroup restated a neutral rating and issued a GBX 1,350 ($18.08) target price on shares of Hikma Pharmaceuticals in a research note on Thursday, August 24th. J P Morgan Chase & Co restated a neutral rating on shares of Hikma Pharmaceuticals in a research note on Friday, September 29th. Peel Hunt reiterated a hold rating and issued a GBX 2,150 ($28.79) price target on shares of Hikma Pharmaceuticals in a report on Thursday, August 17th. Stifel Nicolaus cut Hikma Pharmaceuticals to a hold rating and decreased their price target for the company from GBX 2,300 ($30.80) to GBX 1,320 ($17.68) in a report on Tuesday, August 29th. Finally, Numis Securities reiterated an add rating and issued a GBX 1,560 ($20.89) price target on shares of Hikma Pharmaceuticals in a report on Friday, August 11th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of GBX 1,321.91 ($17.70).
Hikma Pharmaceuticals (LON HIK) traded down GBX 19 ($0.25) during trading on Friday, reaching GBX 1,028 ($13.77). The company’s stock had a trading volume of 1,217,648 shares, compared to its average volume of 1,020,000. Hikma Pharmaceuticals has a 1 year low of GBX 906.50 ($12.14) and a 1 year high of GBX 2,346 ($31.42).
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals PLC and related companies with our FREE daily email newsletter.